The effectiveness of cord blood transplantation (CBT) has recently been explored in an increasing number of adult patients.
The effectiveness of cord blood transplantation (CBT) has recently been explored in an increasing number of adult patients. 1 However, there are limited data on the management of graft rejection that may follow CBT. Here, we report the case of a patient with graft rejection following CBT; the patient was successfully treated with a second reduced-intensity conditioning (RIC) CBT, despite the fact that he was suffering from serious infectious complications.
A 44-year-old Japanese man was diagnosed with AML (M6). He achieved CR with the first course of induction chemotherapy. However, his condition showed a relapse and the patient achieved a second CR after the second course of chemotherapy. Because of the absence of a suitable donor among family members and unrelated donors, CBT was planned and he was referred to our hospital. The conditioning regimen comprised 12 Gy TBI and 120 mg/kg CY. He received an infusion of serologically two HLA-loci mismatched unrelated cord blood containing 2.20 Â 10 7 nucleated cells/kg. Tacrolimus and short-term MTX were administered for GVHD prophylaxis. Treatment with G-CSF was initiated on day þ 5. Neutrophil count increased temporarily but decreased subsequently; therefore, on day þ 19, we performed PCR for amplifying the informative short tandem repeat regions, which demonstrated complete donor chimerism in the PBMC. G-CSF treatment was continued; however, hematological recovery was not observed. On day þ 28, the BM sample revealed a severely hypocellular marrow, PCR analysis indicated complete recipient chimerism in the PBMC, and graft rejection was diagnosed. Simultaneously, CMV and human herpesvirus 6 (HHV6) DNA were detected in the PBMC by real-time PCR; therefore, treatment using 60 mg/ kg foscarnet per day was started. On day þ 34, bacteremia due to Stenotrophomonas maltophilia and endotoxemia developed. Immediate treatment was started with ciprofloxacin and minocycline, and the central venous catheter was removed. To treat graft rejection, a second CBT was scheduled with the continuous administration of antimicrobial agents. The conditioning regimen comprised administration of 30 mg/m 2 fludarabine per day for 6 days and 70 mg/m 2 melphalan per day for 1 day. The patient received an infusion of serologically two HLA-loci mismatched unrelated cord blood containing 2.26 Â 10 7 nucleated cells/kg at an interval of 45 days from the first CBT. Continuous intravenous infusion of 0.02 mg/kg tacrolimus per day was started on day À1 and 500 mg mycophenolate mofetil (MMF) was orally administered twice daily on day þ 1 for GVHD prophylaxis. G-CSF was administered from day þ 1. He tolerated the procedure well with minimal regimen-related toxicity (RRT). Engraftment was achieved with an ANC above 0.5 Â 10 9 /l on day þ 23 and a platelet count above 20 Â 10 9 /l was observed on day þ 58 after the second CBT. The PBMC sample obtained on day þ 26 showed complete second-donor chimerism. Along with recovery of the neutrophil count, bacteremia and endotoxemia improved. However, CMV antigenemia developed again despite continuous administration of foscarnet. Moreover, on day þ 23, HHV6 encephalitis developed. The dosage of foscarnet was increased to 120 mg/kg/day; however, foscarnet was substituted with ganciclovir (5 mg/ kg/day) due to development of flatulence as a side effect. CMV antigen-positive cells disappeared and HHV6 encephalitis improved. The patient then developed acute GVHD (skin stage 1, grade I) and bronchiolitis obliterans with organizing pneumonia, which was controlled by steroid administration. The patient's CR has since been maintained with a Karnofsky performance status of 100%, 5 months after the second CBT.
Graft rejection is a life-threatening complication that occasionally occurs after allogeneic SCT. 2 CBT has been reported to delay engraftment; in addition, CMV and HHV6 infections are reportedly more frequent after CBT as compared to BMT. 3, 4 In this case, the number of cells infused and HLA disparity were consistent with that reported previously, 1 and anti-HLA Ab was negative. Thus, we consider it likely that the CMV and HHV6 infections may have been the factors responsible for the graft rejection and it is possible that the early administration of foscarnet after the diagnosis of graft rejection contributed to the success of the second CBT engraftment. It is thus necessary to focus on the possible association of viral infections in case graft rejection develops. In the management of graft rejection, further immunosuppressive conditioning is required before the second infusion of hematopoietic stem cells. 2 Among patients who underwent a second allo-SCT, high transplant-related mortality and a high rate of RRT were observed; 5 therefore, we selected an RIC regimen for the second CBT. Further, GVHD was reported to be severe after the second transplantation. 6 In the recent report, GVHD prophylaxis regimen using the calcineurin inhibitor and MMF is associated with faster engraftment, decreased incidence of mucositis, similar incidences of GVHD and comparable risk of infection, as compared to using the calcineurin inhibitor with MTX.
We, therefore, selected the combination of tacrolimus and MMF. In the neutropenic period, the patient suffered from bacteremia due to S. maltophilia. This pathogen is resistant to multiple antibiotics, which leads to frequent therapeutic failures. 8 Moreover, HHV6 encephalitis developed during engraftment and this is a serious, potentially life-threatening complication in the post-transplant period. 4 Rapid diagnosis of the serious infectious complications followed by immediate treatment may have improved the prognosis in this case.
In conclusion, we successfully performed a second CBT with an RIC regimen for graft rejection following CBT. The early diagnosis of graft rejection and the early operation of second CBT were considered to contribute to the successful outcome. Further, this case suggests that the RIC regimen renders a second CBT a feasible therapeutic option for patients with graft rejection, as described previously. 9 Although further investigation is required, we believe that this report is informative for establishing optimal conditioning regimens and GVHD prophylaxis for second early CBT. In the management of graft rejection, especially that following CBT, the control of infectious complications is also critically important. 
